Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR3 | P29371 | 3/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | FNTA | P49354 | 1/20 | 0.36 |
| ▸ | FNTB | P49356 | 1/20 | 0.36 |
| ▸ | TACR2 | P21452 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4668596 | 0.92 | OPRM1 (0.45) | TACR3KCNH2OPRM1 | |
| SCHEMBL4665287 | 0.90 | FNTA (0.39) | TACR3CHRM2CHRM3LMNAFNTA | |
| SCHEMBL4667024 | 0.89 | AGER (0.40) | TACR3OPRM1LMNAFNTAFNTB | |
| SCHEMBL4665870 | 0.88 | TACR3 (0.38) | TACR3KCNH2LMNAFNTAFNTB | |
| SCHEMBL4667068 | 0.87 | TACR3 (0.41) | TACR3KCNH2OPRM1LMNATACR2 | |
| SCHEMBL4667560 | 0.82 | MEN1 (0.43) | TACR3OPRM1 | |
| SCHEMBL4667460 | 0.82 | MEN1 (0.42) | TACR3OPRM1 | |
| SCHEMBL4668627 | 0.80 | OPRM1 (0.41) | TACR3OPRM1 | |
| SCHEMBL4665274 | 0.80 | TACR3 (0.45) | TACR3KCNH2 | |
| SCHEMBL4667114 | 0.79 | PDE10A (0.42) | TACR3LMNAFNTAFNTB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080234269-A1 | N-Oxo-Heterocycle and N-Oxo-Alkyl Quinoline-4-Carboxamides as Nk-3 Receptor Ligands | ASTRAZENECA AB (SE) | 2008-09-25 | — | — | US | claimed |
| CN-101268052-A | N-oxo-heterocycle and N-oxo-alkyl quinoline-4-carboxamides as NK-3 receptor ligands | ASTRAZENECA AB (SE) | 2008-09-17 | — | — | CN | claimed |
| US-20080234269-A1 | N-Oxo-Heterocycle and N-Oxo-Alkyl Quinoline-4-Carboxamides as Nk-3 Receptor Ligands | ASTRAZENECA AB (SE) | 2008-09-25 | — | — | US | disclosed |
| CN-101268052-A | N-oxo-heterocycle and N-oxo-alkyl quinoline-4-carboxamides as NK-3 receptor ligands | ASTRAZENECA AB (SE) | 2008-09-17 | — | — | CN | disclosed |
| EP-1940795-A1 | N-OXO-HETEROCYCLE AND N-OXO-ALKYL QUINOLINE-4-CARBOXAMIDES AS NK-3 RECEPTOR LIGANDS | AstraZeneca AB (SE) | 2008-07-09 | — | — | EP | disclosed |
| WO-2007035156-A1 | N-OXO-HETEROCYCLE AND N-OXO-ALKYL QUINOLINE-4-CARBOXAMIDES AS NK-3 RECEPTOR LIGANDS | ASTRAZENECA AB (SE) | 2007-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234269-A1 | N-Oxo-Heterocycle and N-Oxo-Alkyl Quinoline-4-Carboxamides as Nk-3 Receptor Ligands | TACR3, TACR2, KCNA3 | TACR3 1/4885KCNH2 36/4885CHRM2 163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.